Literature DB >> 15494581

Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome.

Gustavo Saposnik1, Bryan Young, Brian Silver, Silvia Di Legge, Fiona Webster, Vadim Beletsky, Vivek Jain, Yongchai Nilanont, Vladimir Hachinski.   

Abstract

CONTEXT: The focus of thrombolytic therapy in acute stroke has been on favorable outcome at 3 months. Few studies have analyzed outcome at 24 hours. An early and reliable prediction of poor outcome has implications for clinical management and discharge planning.
OBJECTIVE: To evaluate predictors of lack of improvement at 24 hours after receiving alteplase and their relationship with poor outcome at 3 months. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort of consecutive patients with acute stroke who received alteplase and were admitted to a university hospital from January 1999 to March 2003. Participants were recruited from 2 academic centers in a major city in Ontario and 33 affiliated hospitals from 7 counties. MAIN OUTCOME MEASURES: Lack of improvement defined as a difference between the National Institutes of Health Stroke Scale score at baseline and at 24 hours of 3 points or less. Poor outcome at 3 months defined by a modified Rankin Scale score of 3 to 5 or death.
RESULTS: Among 216 patients with acute stroke who were treated with alteplase, 111 (51.4%) had a lack of improvement at 24 hours. After adjusting for age, sex, and stroke severity, baseline glucose level on admission (odds ratio [OR] 2.89; 95% confidence interval [CI], 1.40-5.99 for a glucose level >144 mg/dL [>8 mmol/L]), cortical involvement (OR, 2.66; 95% CI, 1.36-5.20), and time to treatment (OR, 1.01; 95% CI, 1.0-1.02 for each 1 minute increase in time to treatment) were independent predictors of lack of improvement. At 3 months, 43 patients (20.2%) had died; of the 170 survivors, 75 patients (44%) had poor outcomes. After adjusting for age, sex, and stroke severity, lack of improvement at 24 hours was an independent predictor of poor outcome (OR, 12.9; 95%CI, 5.7-29.6) and death (OR, 7.5; 95% CI, 2.9-19.6). Patients with a lack of improvement had longer lengths of hospitalization (14.5 vs 9.6 days; P = .02).
CONCLUSIONS: Among patients with acute stroke treated with thrombolytic therapy, lack of improvement at 24 hours is associated with poor outcome and death at 3 months. Elevated glucose level, time to thrombolytic therapy, and cortical involvement were predictors of lack of improvement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494581     DOI: 10.1001/jama.292.15.1839

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

Review 1.  Treating hyperglycemia in neurocritical patients: benefits and perils.

Authors:  Daniel A Godoy; Mario Di Napoli; Alejandro A Rabinstein
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

Review 2.  Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management.

Authors:  Nyika D Kruyt; Geert Jan Biessels; J Hans Devries; Yvo B Roos
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

Review 3.  Effects of AMP-activated protein kinase in cerebral ischemia.

Authors:  Jun Li; Louise D McCullough
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-16       Impact factor: 6.200

Review 4.  Glycemic variability and acute ischemic stroke: the missing link?

Authors:  Emmanuel I González-Moreno; Carlos R Cámara-Lemarroy; José G González-González; Fernando Góngora-Rivera
Journal:  Transl Stroke Res       Date:  2014-08-03       Impact factor: 6.829

5.  JURaSSiC: accuracy of clinician vs risk score prediction of ischemic stroke outcomes.

Authors:  Gustavo Saposnik; Robert Cote; Muhammad Mamdani; Stavroula Raptis; Kevin E Thorpe; Jiming Fang; Donald A Redelmeier; Larry B Goldstein
Journal:  Neurology       Date:  2013-06-28       Impact factor: 9.910

6.  Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100.

Authors:  Gustavo Saposnik; Amy K Guzik; Mathew Reeves; Bruce Ovbiagele; S Claiborne Johnston
Journal:  Neurology       Date:  2012-11-21       Impact factor: 9.910

7.  Thrombolysis for cerebral ischemia.

Authors:  Jennifer E Fugate; Elias A Giraldo; Alejandro A Rabinstein
Journal:  Front Neurol       Date:  2010-10-29       Impact factor: 4.003

Review 8.  AMPK: Potential Therapeutic Target for Ischemic Stroke.

Authors:  Shuai Jiang; Tian Li; Ting Ji; Wei Yi; Zhi Yang; Simeng Wang; Yang Yang; Chunhu Gu
Journal:  Theranostics       Date:  2018-08-10       Impact factor: 11.556

9.  Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis.

Authors:  Alexandre Y Poppe; Sumit R Majumdar; Thomas Jeerakathil; William Ghali; Alastair M Buchan; Michael D Hill
Journal:  Diabetes Care       Date:  2009-01-08       Impact factor: 17.152

10.  Determinants of outcome in patients eligible for thrombolysis for ischemic stroke.

Authors:  Valeria Caso; Maurizio Paciaroni; Michele Venti; Francesco Palmerini; Giorgio Silvestrelli; Paolo Milia; Sergio Biagini; Giancarlo Agnelli
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.